Every year, the risk of a US government funding lapse sends ripples through global supply chains. For businesses across Asia trading pharmaceutical ingredients, food products, or medical devices with the American market, understanding how the Food and Drug Administration (FDA) operates — and what it stops doing — during a shutdown is not just useful background knowledge. It is a practical risk management imperative.

This article draws directly from the FDA’s official contingency staffing plan to explain what continues, what stops, and what steps businesses should take to protect their supply chains.

What Triggers an FDA Shutdown?

A government shutdown occurs when the US Congress fails to pass an appropriations bill before the fiscal year deadline. Without a funding law in place, federal agencies — including the FDA — lose access to their annual operating budget.

The FDA’s work is split between two main funding sources: congressionally appropriated funds and user fees paid directly by industry. Activities reliant on appropriated funds are the first to be suspended; those backed by user fee carryover can often continue.

FDA Activities That Continue During a Funding Lapse

The FDA’s user fee programs — funded directly by pharmaceutical, biotechnology, and medical device companies — allow several critical review and authorization functions to continue uninterrupted:

• Review and marketing authorization of new drugs, generic drugs, biosimilars, and vaccines
• Pre-market review and clearance of medical device submissions
• Clinical trial request reviews and issuance of guidance documents
• Full regulation of tobacco products — this program is entirely user fee-funded

Beyond user fee activities, the FDA retains authority to act on any matter posing an imminent threat to human life or property. This covers:

• Detection and response to public health emergencies, including disease outbreaks
• Management of product recalls and monitoring of drug shortage situations
• Response to foodborne illness outbreaks and infectious disease events
• Surveillance of adverse event reports for safety signals requiring urgent action
• Import entry review to screen for immediate risks to public health
• For-cause inspections and targeted surveillance inspections of regulated facilities
• Criminal enforcement operations and certain civil investigations

ISF: Complete Guide to Importer Security Filing (10+2) Requirements

FDA Activities That Stop or Are Severely Curtailed

The impact of a funding lapse extends across nearly every major FDA program that relies on annual congressional appropriations. These are not minor inconveniences — they represent real gaps in the safety net that protects consumers and enables businesses to bring products to market.

Pharmaceutical & Biological Products

• New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Biologics License Applications (BLAs) requiring user fee payment will not be accepted
• The Human Drugs Program halts most activities related to unapproved prescription drugs
• Oversight of compounded drug safety is suspended unless an imminent threat is identified

Animal Drugs & Food Safety

• Pre-market safety reviews of novel animal food ingredients are suspended, creating a gap in assurance that livestock-derived products — meat, milk, and eggs — are safe for human consumption
• The Human Foods Program narrows its scope to safety surveillance and emergency response only
• Long-term food safety policy work — including initiatives to prevent foodborne illness and diet-related disease — is halted entirely

Medical Products & Research

• Regulatory testing of medical products is limited to scenarios involving imminent threats to human life
• Regulatory science research — the foundation for advancing product innovation, safety standards, and quality benchmarks — is curtailed
• Policy development for national and global health security preparedness is paused

Administrative & Infrastructure Functions

• Recruitment, hiring, and staff development programs are suspended
• Investments in laboratory equipment, research infrastructure, and technology innovation are postponed
• The number and scope of routine inspections are significantly restricted
• Review work, guidance development, and pre-approval inspections for whole blood, blood components for transfusion, and antivenom cease completely

What This Means for Asia–USA Trade

For Asian exporters and importers dealing in FDA-regulated categories, the risks during a shutdown period fall into three broad areas:

1. Import Entry Delays & Hold Risk

Even though import entry review for immediate health risks continues, reduced FDA staffing means slower processing times for shipments in grey-zone categories. Goods with incomplete documentation, unusual HS codes, or prior compliance flags are at elevated risk of being placed on hold — with no guarantee of expedited resolution while the shutdown persists.

Our experience: During past shutdown events, pharmaceutical ingredient shipments from Southeast Asia took 30–45% longer to clear than normal. Shipments with any prior FDA Import Alert history were effectively frozen.

2. Pre-market Review Backlogs

If you are waiting on FDA review of a new product registration, ANDA, or device 510(k) clearance, expect these timelines to extend. Even user fee-funded reviews may face indirect delays if supporting staff are furloughed.

3. Compliance Documentation Gaps

With FDA guidance development paused and regulatory science activities curtailed, businesses may find it harder to get clarification on labelling, ingredient approval, or novel food safety standards. This creates uncertainty for new product launches into the US market.

Risk Summary by Category

AMS and US ACE: Complete Guide to Automated Manifest System and Customs Environment

Practical Steps to Protect Your Supply Chain

Based on our team’s direct experience managing FDA-regulated shipments during prior US government shutdowns, here are the actions we recommend for Asian exporters:

Before a Shutdown is Declared

• Audit all pending FDA submissions (NDAs, ANDAs, 510(k)s, GRAS notices) and check their current review stage — any submission not yet accepted is vulnerable
• Review your import history for any prior FDA flags, holds, or refusals — these will face heightened scrutiny
• Ensure all shipping documentation is complete and pre-validated before goods leave origin
• Brief your US customs broker and freight forwarder on shutdown contingency procedures

During a Shutdown

• Avoid shipping borderline products without prior broker consultation — holds during a shutdown can last weeks
• Maintain direct communication with your G.O.L account manager for real-time regulatory updates
• Document all communications with FDA or CBP for post-shutdown follow-up

After a Shutdown Ends

• Expect a post-shutdown surge in FDA processing — backlogs clear slowly; plan for 4–8 weeks of elevated review times
• Re-engage any paused submissions immediately upon FDA reopening — queue position matters
• Request post-shutdown compliance briefings from G.O.L to understand any regulatory changes that occurred

How G.O.L Supports Your Business Through Regulatory Uncertainty

G.O.L is a trade compliance specialist and logistics solution provider that helps businesses stay compliant across trade markets. Our team monitors regulatory developments in real time — including FDA policy changes, US Customs alerts, and trade compliance updates — so your cargo keeps moving even when the regulatory environment shifts.

Our Services for FDA-Regulated Trade

• FDA import compliance advisory for Asia–USA pharmaceutical, food, and device trade
• Customs clearance and documentation support for FDA-regulated goods
• Dedicated account management — reach us directly at +65 8342 6900

G.O.L SOLUTION

160 Robinson Road #14-04 Singapore 068914

clients@golsolution.com  |  +65 8342 6900